Vaxcyte (NASDAQ:PCVX) CAO Elvia Cowan Sells 3,000 Shares of Company Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CAO Elvia Cowan sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $60.92, for a total transaction of $182,760.00. Following the transaction, the chief accounting officer owned 27,860 shares in the company, valued at $1,697,231.20. The trade was a 9.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elvia Cowan also recently made the following trade(s):

• On Monday, October 5th, Elvia Cowan sold 19,000 shares of Vaxcyte stock. The shares were sold at an average price of $86.74, for a total transaction of $1,648,060.00.

Vaxcyte Price Performance

Shares of Vaxcyte stock opened at $65.68 on Thursday. The firm has a market cap of $9.77 billion, a P/E ratio of -8.61 and a beta of 1.31. The firm has a 50 day simple moving average of $61.64 and a 200 day simple moving average of $57.16. Vaxcyte, Inc. has a fifty-two week low of $39.87 and a fifty-two week high of $90.75.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($1.99) earnings per share for the quarter, topping the consensus estimate of ($2.11) by $0.12. During the same quarter in the prior year, the firm posted ($1.56) earnings per share. On average, sell-side analysts expect that Vaxcyte, Inc. will post -7.47 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday, October 2nd. BTIG Research reiterated a “buy” rating and issued a $89.00 price target on shares of Vaxcyte in a report on Monday, October 5th. Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Bank of America lowered their price objective on Vaxcyte from $133.00 to $130.00 and set a “buy” rating for the company in a research report on Monday, September 28th. Finally, Guggenheim boosted their price objective on Vaxcyte from $116.00 to $125.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Vaxcyte currently has an average rating of “Moderate Buy” and a consensus price target of $110.50.

Hedge Funds Weigh In On Vaxcyte

Several large investors have recently bought and sold shares of PCVX. First Light Asset Management LLC lifted its stake in Vaxcyte by 143.4% in the second quarter. First Light Asset Management LLC now owns 345,157 shares of the company’s stock valued at $20,064,000 after buying an additional 203,373 shares during the period. Bank of America Corp DE boosted its holdings in Vaxcyte by 73.4% during the first quarter. Bank of America Corp DE now owns 1,216,843 shares of the company’s stock worth $70,711,000 after buying an additional 515,209 shares during the last quarter. Candriam S.C.A. acquired a new position in shares of Vaxcyte during the 1st quarter worth about $18,306,000. Seven Fleet Capital Management LP grew its position in shares of Vaxcyte by 406.4% during the 1st quarter. Seven Fleet Capital Management LP now owns 128,450 shares of the company’s stock worth $7,464,000 after buying an additional 103,085 shares during the period. Finally, Engineers Gate Manager LP acquired a new position in shares of Vaxcyte during the 2nd quarter worth about $1,906,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.